Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 0.45%.

  • SAB Biotherapeutics' Return on Capital Employed rose 6100.0% to 0.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.45%, marking a year-over-year increase of 6100.0%. This contributed to the annual value of 0.77% for FY2024, which is 900.0% down from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Return on Capital Employed is 0.45%, which was up 6100.0% from 1.78% recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Return on Capital Employed high stood at 0.18% for Q4 2021, and its period low was 1.78% during Q2 2025.
  • For the 5-year period, SAB Biotherapeutics' Return on Capital Employed averaged around 0.85%, with its median value being 0.81% (2023).
  • Within the past 5 years, the most significant YoY rise in SAB Biotherapeutics' Return on Capital Employed was 6100bps (2025), while the steepest drop was -10100bps (2025).
  • SAB Biotherapeutics' Return on Capital Employed (Quarter) stood at 0.18% in 2021, then tumbled by -327bps to 0.79% in 2022, then dropped by -7bps to 0.84% in 2023, then dropped by -25bps to 1.05% in 2024, then surged by 57bps to 0.45% in 2025.
  • Its Return on Capital Employed was 0.45% in Q3 2025, compared to 1.78% in Q2 2025 and 1.34% in Q1 2025.